Skip to main content
Premium Trial:

Request an Annual Quote

Merck, Promega Collaborate to Develop MSI CDx for Keytruda

NEW YORK – Promega announced on Wednesday that it has signed a global collaboration deal with Merck to develop an on-label, solid tumor companion diagnostic for Merck's anti-PD1 immunotherapy pembrolizumab (Keytruda) using Promega's microsatellite instability (MSI) technology.

Promega's MSI Analysis System is a fluorescent multiplex PCR-based method for the detection of microsatellite instability. It includes seven multiplexed markers for analysis of the MSI-high phenotype — five nearly monomorphic mononucleotide repeat markers and two highly polymorphic pentanucleotide repeat markers, which are used for quality control and sample authentication of matched normal and tumor tissues.

The companies are planning to seek regulatory approval for the Promega MSI CDx in the US and China and may seek approvals in other countries in the future, Promega said. Financial terms of the collaboration deal were not disclosed.

"It is gratifying to see our MSI technology have such meaning within the oncology community," Promega President and CEO Bill Linton said in a statement. "Promega developed this technology well over a decade ago, and our long-term commitment to R&D helped evolve its use."

In addition to the collaboration with Merck, Promega said it intends to seek regulatory clearance for an MSI in vitro diagnostic test in the US, China, and Europe. The company intends to launch these products in the first half of 2020.

In February, Promega announced that Japan's Ministry of Health, Labour, and Welfare had approved the MSI CDx for pembrolizumab. The CDx is distributed in Japan by Kyoto-based Falco Biosystems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.